Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Transformation

Set Alert for Digital Transformation

Big Pharma Restructures Commercial Teams In India

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

India Commercial

Korea Readying Itself For New Era Of Digital Therapeutics

Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.

South Korea Digital Health

AI/ML Grows In Importance, Holds Promise in mRNA

Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.

Artificial Intelligence Vaccines

Beyond Pill Sensors, Digital Tech Can Provide Insights On How Patients Use Drugs

During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.

Artificial Intelligence Digital Health

Will RWD Get Real In Japan? Govt Moves To Build Digital Health Records

To enable broader use of clinical data in its digital health care system, Japan has kickstarted digitization measures to link all patient records to an online individual ID system. While the government aims to allow real-world data and evidence for the pharmaceutical sector in the long run, Scrip explores the reality of current projects and measures in the country.

Japan Real-World Evidence

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J and Roche’s first-half wins and challenges; Alexion’s Ultomiris plans; GSK’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.

Artificial Intelligence Commercial

New ‘Dark Genome’ Biotech Gets Backing From Big Pharma Venture Funds

The Oxford University spin-out has raised $37.5m in a series A thanks to its technology which pinpoints the link between genes and diseases and maps pathways for drug discovery.

StartUps and SMEs Financing

US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview with Scrip the US Inflation Reduction Act, telehealth,  interoperability of healthcare data, and Mark Cuban’s pharma venture.

Legislation United States

Doing It The Nike Way – Novartis, AstraZeneca On Making The Metaverse Work

From AstraZeneca’s training program for its representatives to Pfizer’s campaign to drive vaccination in Brazil, the industry is taking a leaf out of Nike’s playbook in adopting the metaverse. Novartis’ executive director and AZ’s director of learning discussed applications and challenges at a recent event.

Commercial Digital Health

Side Actor To Centre Stage: How Pharma Is Transforming Its Global Content Supply Chain

Executives from GlaxoSmithKline, Boehringer Ingelheim, Novo Nordisk, Eli Lilly and Ipsen outline at a recent summit pharma’s efforts to meet the growing demands on content for personalized marketing across markets. Delivering "glocal' content at scale, a master versus modular strategy, creative studios and the role of the digital production factory were some of the key talking points.

Commercial Digital Health

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Pfizer takes on AstraZeneca and Merck & Co in prostate cancer; AstraZeneca’s gene therapy acquisition; ex-Sanofi partnering head joins AI start-up; Shionogi and Medicines Patent Pool strike deal for oral COVID antiviral; and Intercept sticks with NASH plans despite missed endpoint.

Business Strategies Commercial

Cellarity Takes Broader, Whole-Cell Approach To Drug Discovery

CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.

Artificial Intelligence Financing
See All
UsernamePublicRestriction

Register